
We're honored to receive the @CALifeSciences Pantheon Award for Biopharma Product of the Year. Thank you to the patients, families, investigators, care teams, and colleagues whose partnership makes our work possible. califesciences.org/insights/…
✓We aim to change the trajectory of disease for patients living with RAS-addicted cancers around the world. Community guidelines: bit.ly/4xUSQQs

We're honored to receive the @CALifeSciences Pantheon Award for Biopharma Product of the Year. Thank you to the patients, families, investigators, care teams, and colleagues whose partnership makes our work possible. califesciences.org/insights/…

The European Commission has granted marketing authorization for our oral RAS(ON) multi-selective inhibitor for previously treated metastatic pancreatic cancer. Read more: revmed.com/media/news/13736/… #ForMediaOnly

RAS mutations are linked to the development of many cancers, including pancreatic cancer and non-small cell lung cancer. Biomarker testing can identify specific RAS mutations, helping to inform treatment decisions. Learn more: expectras.com/

More than 60,000 people in the U.S. will be diagnosed with pancreatic cancer in 2026. This Pancreatic Cancer Awareness Month, we’re recognizing everyone affected by pancreatic cancer and the researchers working to better understand this complex disease.

This month, Revolution Medicines will donate $50 to @KRASKickers for every message of support submitted for up to $30,000. Plant a seed of hope. Share your message: revmed.com/revolution-ras/?u…

Caregiving often happens quietly: coordinating appointments, managing everyday tasks and being there to listen. This National Family Caregivers Month, we recognize those supporting loved ones through pancreatic and lung cancer. Your well-being matters, too.

Today we reported our Q3 2026 financial results including the milestone U.S. FDA approval and launch of our multi-selective RAS(ON) inhibitor for eligible adults with previously treated metastatic pancreatic cancer. Read more: revmed.com/media/news/13691/…

This November, we’re recognizing everyone affected by pancreatic and lung cancer. Together, we can spread awareness, show support, and make a difference.

Today at ESMO26, we presented new subgroup analyses of our multi-selective RAS(ON) inhibitor across RAS variants and treatment settings in previously treated metastatic pancreatic cancer. Read more: revmed.com/media/news/13651/… #ForMediaOnly

We’re excited for ESMO2026, where we’ll share subgroup analyses from RASolute 302 and connect with colleagues across the oncology community. Swipe through to see where you can find Revolution Medicines throughout the congress. #ForMediaOnly

Patients have begun treatment in RASolve 308, a global Phase 3 trial evaluating our investigational RAS(ON) G12D-selective inhibitor plus pembrolizumab and platinum-based chemotherapy as first-line treatment for metastatic RAS G12D non-squamous NSCLC. revmed.com/media/news/13631/…

Honored to receive @TIME 2026 Best Inventions in the Medical & Healthcare category. A recognition of our team’s commitment to bold scientific innovation and to creating new possibilities for patients. time.com/collection/best-inv…

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for our multi-selective RAS(ON) inhibitor for adults with metastatic pancreatic cancer in the EU. Read more: revmed.com/media/news/13621/… #ForMediaOnly

Congratulations to Jan Smith, PhD, Chief Scientific Officer, on this well-deserved recognition. Her leadership at RevMed brings together different perspectives and empowers teams to ask bold questions, follow the evidence, and advance science together.

Patient treatment is underway in RASolute 309, our global Phase 3 trial evaluating the combination of our RAS(ON) multi-selective inhibitor and investigational RAS(ON) G12D-selective inhibitor as first-line treatment for metastatic RAS G12D PDAC. More: revmed.com/media/news/13576/…

The U.S. FDA granted Breakthrough Therapy Designation to our RAS(ON) multi-selective inhibitor in combination with GnP for previously untreated metastatic pancreatic adenocarcinoma, an investigational treatment setting for this combination. Learn more: revmed.com/media/news/13431/…